Combining IMRT and lobaplatin chemo for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether combining a newer chemotherapy drug (lobaplatin) with standard radiation and chemotherapy is safe and effective for adults aged 65 to 80 with a certain type of nasopharyngeal cancer that hasn't spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma, confirmed by a biopsy.
- Your cancer is stage II, III, or IVa according to the UICC 8th edition staging system.
- You are between the ages of 65 and 80.
- Your liver, kidney, and blood cell counts are within a healthy range for your age.
- You are able to walk and care for yourself (a performance status of 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding chemotherapy to a combination of immunotherapy and radiation is more effective than immunotherapy and radiation alone for advanced nasopharyngeal cancer. It is for people whose cancer has not spread to distant organs.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
Hear when a new Elderly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.